Acurx Pharmaceuticals financials
$1.31−2.61%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$2.3M | -$1.7M | -$1.6M | -$2.0M | -$2.3M | -$2.2M | -$2.8M | -$2.8M | -$4.1M | -$4.4M | -$5.1M | -$3.1M |
| Net income | -$2.3M | -$1.7M | -$1.6M | -$2.0M | -$2.2M | -$2.1M | -$2.8M | -$2.8M | -$4.1M | -$4.4M | -$5.1M | -$3.1M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.53 | $-0.62 | $-0.72 | $-1.23 | $-1.89 | $-2.15 | $-1.17 | $-3.45 | $-5.21 | $-5.60 | $-7.38 | $-4.80 |
| EBITDA | -$2.3M | -$1.7M | -$1.6M | -$2.0M | -$2.3M | -$2.2M | -$2.8M | -$2.8M | -$4.1M | -$4.4M | -$5.1M | -$3.1M |
| Operating cash flow | -$1.7M | -$1.4M | -$1.2M | -$1.9M | -$1.7M | -$2.1M | -$2.3M | -$2.2M | -$2.9M | -$3.1M | -$4.2M | -$2.1M |
| Free cash flow | -$1.7M | -$1.4M | -$1.2M | -$1.9M | -$1.7M | -$2.1M | -$2.3M | -$2.2M | -$2.9M | -$3.1M | -$4.2M | -$2.1M |
| Diluted shares | 4.3M | 2.7M | 2.2M | 1.6M | 1.2M | 1.0M | 2.4M | 0.8M | 0.8M | 0.8M | 0.7M | 0.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $10.7M | $9.3M | $7.6M | $5.9M | $6.1M | $4.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $11.0M | $9.5M | $7.7M | $6.1M | $6.2M | $4.8M |
| Total liabilities | $2.8M | $2.5M | $2.4M | $2.5M | $2.6M | $2.5M |
| Shareholders' equity | $8.2M | $7.0M | $5.3M | $3.6M | $3.6M | $2.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology